Investors focused on the Medical space have likely heard of ABIOMED , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

ABIOMED is one of 817 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ABMD is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past 90 days, the Zacks Consensus Estimate for ABMD's full-year earnings has moved 0.31% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the most recent data, ABMD has returned 88.20% so far this year. In comparison, Medical companies have returned an average of 0.02%. This means that ABIOMED is performing better than its sector in terms of year-to-date returns.

Breaking things down more, ABMD is a member of the Medical - Instruments industry, which includes 92 individual companies and currently sits at #94 in the Zacks Industry Rank. This group has gained an average of 11.99% so far this year, so ABMD is performing better in this area.

Going forward, investors interested in Medical stocks should continue to pay close attention to ABMD as it looks to continue its solid performance.